Discovery Life Sciences Engager | Cancelled

Discovery Life Sciences Logo

Hanson Wade have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause.

Please register your interest below if you would like updates on the meeting or topic.

Recent Advances to Accelerate & Scale Cell & Gene Therapies

Eliminating Bottlenecks & Advancing Cell Therapy Research, Development & Manufacturing

This Discovery Life Sciences Engager has been created to provide cell and gene therapy C-Level leaders, VPs, Directors and Heads in R&D, allogeneic development and cell engineering departments with the opportunity to address the challenges and bottlenecks that are holding back research, development and manufacturing progress, as well as reviewing the benefits of comprehensive multi-omic services and how it can streamline and accelerate cell therapy research.

Join us for this exclusive event to delve deep into how pre-characterized human cellular materials will accelerate cell therapy development and address the ever-increasing demand for cellular starting materials and review how to increase specific sample cohorts.

This is your chance to discuss the current state of the market, its future direction, and discover how to accelerate your research and development to improve process development, manufacturing, and supply chain for cell and gene therapies.

CANCELLED: Recent Advances in Scalable Manufacturing of Cell & Gene Therapies

6:00 pm Registration & Welcome Reception

6:30 pm Opening Remarks

6:35 pm Panel Discussion & Q&A: Optimizing Next Generation Cell Therapy Starting Materials

  • Dominic Clarke Chief Technical Officer of
    Cell & Gene Therapies, Discovery Life Sciences
  • Knut Niss Chief Technology Officer, Mustang Bio
  • Greg Whitehead Chief Quality Officer, Rubius Therapeutics
  • Sheila Smith Senior Director, Clinical Operations, AllCells

Synopsis

• Discuss how pre-characterized human cellular materials will accelerate cell therapy development
• Address the ever-increasing demand for cellular starting materials and review how to increase specific sample cohorts
• Deep dive into the benefits of comprehensive multi-omic services and how it can streamline and accelerate cell therapy research
• Hear how Discovery Life Sciences can unlock a new cell therapy paradigm and discover how it can provide expertise and guidance to accelerate research at every stage of development

7:15 pm Networking & Drinks

Synopsis

Informal and exclusive opportunity to engage with senior pharma leaders interested in manufacturing and supply chain for cellular therapeutics

8:00 pm End of Discovery Life Sciences Engager

About Discovery Life Sciences:

Discovery Life Sciences Logo

Discovery Life Sciences is a leading provider of highly characterized human cellular starting materials and expert multi-omic analytical services to advance cell and gene therapy research, development, and manufacturing. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Driven by leading scientific expertise and innovative use of current technologies, the Discovery team engages and consults with customers to more rapidly overcome obstacles and obtain results to make critical research, development and manufacturing decisions at market-leading speed.  We are Science at your Service™!

For more information, visit dls.com/cell-and-gene-therapy-products.